Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Novartis, 2012 Is Set To Be A Bumpy Ride

This article was originally published in The Pink Sheet Daily

Executive Summary

With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.

You may also be interested in...



Bayer’s Reinhardt Returning To Novartis To Replace Departing Vasella

Novartis says long-time chairman Daniel Vasella has decided to leave the Swiss drug maker and its board has chosen former COO and current Bayer healthcare division head Jorg Reinhardt to replace him.

Lundbeck Cuts Its European Sales Teams By A Third, As It Builds Up Its Presence In the U.S. And Emerging Markets

Lundbeck becomes the latest company in Europe to announce job cuts, as austerity, generic competition and unclear pricing and reimbursement practices create uncertainties.

Lundbeck Cuts Its European Sales Teams By A Third, As It Builds Up Its Presence In the U.S. And Emerging Markets

Lundbeck becomes the latest company in Europe to announce job cuts, as austerity, generic competition and unclear pricing and reimbursement practices create uncertainties.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel